SEC Comment Letter 0000000000-23-004309 to Genprex, Inc. (GNPX)
Genprex, Inc.
Date: April 27, 2023 · CIK: 0001595248 · Accession: 0000000000-23-004309
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271386
Letter
United States securities and exchange commission logo April 27, 2023 J. Rodney Varner Chief Executive Officer Genprex, Inc. 3300 Bee Cave Road, #650-227 Austin, TX 78746 Re:Genprex, Inc. Registration Statement on Form S-3 Filed April 21, 2023 File No. 333-271386 Dear J. Rodney Varner: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kate Basmagian
Show Raw Text
United States securities and exchange commission logo
April 27, 2023
J. Rodney Varner
Chief Executive Officer
Genprex, Inc.
3300 Bee Cave Road, #650-227
Austin, TX 78746
Re:Genprex, Inc.
Registration Statement on Form S-3
Filed April 21, 2023
File No. 333-271386
Dear J. Rodney Varner:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Kate Basmagian